Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Apalutamide→

Apalutamide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
956104-40-8
Molecular formula
C21H15F4N5O2S
Molecular weight
477.4 g/mol
Drug class
Non-steroidal androgen receptor (AR) antagonisttargeted antineoplastic
Mechanism of action
Binds directly to the ligand-binding domain of the androgen receptor, inhibits androgen binding and prevents AR nuclear translocation, DNA binding and AR-mediated transcription.
Indications / reported uses
  • Treatment of non-metastatic castration-resistant prostate cancer (nmCRPC)
  • Treatment of metastatic castration-sensitive prostate cancer (mCSPC) in combination with androgen-deprivation therapy

Sources: US DailyMed — ERLEADA (apalutamide) prescribing information · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Apalutamide Environmental Risk Assessment (ERA) (the Apalutamide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.